Search results for " type II"

showing 10 items of 542 documents

Uncoupling of eNOS in Cardiovascular Disease

2017

Abstract Under physiological conditions, nitric oxide (NO) produced by the endothelial NO synthase (eNOS) represents a key vasoprotective factor. Under conditions of cardiovascular diseases, such as hypertension, diabetes, and atherosclerosis, eNOS may become uncoupled. Uncoupled eNOS generates superoxide at the expense of NO and contributes significantly to endothelial dysfunction and atherogenesis. Major mechanisms of eNOS uncoupling include depletion of tetrahydrobiopterin, an essential cofactor for the eNOS enzyme, and deficiency of l -arginine, the eNOS substrate, and/or eNOS S-glutathionylation. Reversal of eNOS uncoupling may represent a novel therapeutic strategy for the prevention …

0301 basic medicinemedicine.medical_specialtyArgininebiologySuperoxidebusiness.industryNitric Oxide Synthase Type IIITetrahydrobiopterin030204 cardiovascular system & hematologybiology.organism_classificationmedicine.diseaseVasoprotectiveNitric oxide03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineEndocrinologychemistryEnosInternal medicinemedicineEndothelial dysfunctionbusinessmedicine.drug
researchProduct

Effects of resveratrol on eNOS in the endothelium and the perivascular adipose tissue

2017

Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial NO synthase (eNOS). Experiments using gene-disrupted mice have demonstrated that eNOS has antihypertensive, antithrombotic, and antiatherosclerotic effects. Recent studies show that eNOS is expressed not only in the endothelium but also in the perivascular adipose tissue (PVAT). Resveratrol prevents eNOS uncoupling and upregulates eNOS expression and activity. These effects of resveratrol are well established for the eNOS enzyme in the endothelium. Interestingly, resveratrol also improves PVAT function. However, a causal role for eNOS in the effects of resveratrol on PVAT function has …

0301 basic medicinemedicine.medical_specialtyEndotheliumAdipose tissue030204 cardiovascular system & hematologyResveratrolGeneral Biochemistry Genetics and Molecular BiologyNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHistory and Philosophy of ScienceEnosInternal medicineAntithromboticmedicinebiologyChemistryGeneral NeuroscienceNitric Oxide Synthase Type IIIbiology.organism_classificationNitric oxide synthase030104 developmental biologyEndocrinologymedicine.anatomical_structurebiology.proteinAnnals of the New York Academy of Sciences
researchProduct

Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased suscepti…

2021

There is a growing body of evidence demonstrating the significant involvement of the sigma-1 chaperone protein in the modulation of seizures. Several sigma-1 receptor (Sig1R) ligands have been demonstrated to regulate the seizure threshold in acute and chronic seizure models. However, the mechanism by which Sig1R modulates the excitatory and inhibitory pathways in the brain has not been elucidated. The aim of this study was to compare the susceptibility to seizures of wild type (WT) and Sig1R knockout (Sig1R−/−) mice in intravenous pentylenetetrazol (PTZ) and (+)-bicuculline (BIC) infusion-induced acute seizure and Sig1R antagonist NE-100-induced seizure models. To determine pos…

0301 basic medicinemedicine.medical_specialtyKnockoutGene ExpressionNitric Oxide Synthase Type IISigma-1 receptorConvulsantsAnisolesSigma-1 receptor Knockout GABA-B receptor Seizures Medial habenula NE-100BicucullineHippocampuslcsh:RC321-571Mice03 medical and health sciences0302 clinical medicineDownregulation and upregulationSeizuresInternal medicineGene expressionmedicineAnimalsReceptors sigmaGABA-B receptorGenetic Predisposition to DiseasePentylenetetrazolReceptorlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryMice KnockoutHabenulaSigma-1 receptorPropylaminesSeizure thresholdChemistryMedial habenulaWild typeAntagonistReceptors GABA-A030104 developmental biologyEndocrinologyReceptors GABA-BNeurologyNE-100Pentylenetetrazole030217 neurology & neurosurgerymedicine.drugNeurobiology of Disease
researchProduct

Participation of Heme Oxygenase-1 in a Model of Acute Inflammation

2003

In this study, the role of heme oxygenase-1 (HO-1) in the inflammatory response elicited by zymosan in the mouse air pouch model has been examined. This response is characterized by a time-dependent increase in HO-1 expression in the leukocytes migrating into the exudates. At 24–48 h maximal HO-1 expression was accompanied by reduced cyclooxygenase-2 (COX-2) and nitric oxide synthase-2 (NOS-2) expression as well as low levels of inflammatory mediators. Hemin administration into the air pouch caused an elevation of HO-1 protein and bilirubin levels induced by zymosan with inhibition of COX-2 expression. In mouse peritoneal macrophages from hemin-injected mice, we also observed an increased …

0301 basic medicinemedicine.medical_specialtyNitric Oxide Synthase Type IIInflammationGeneral Biochemistry Genetics and Molecular BiologyNitric oxideMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineAnimalsProstaglandin E2HemeInflammationbiologyZymosanZymosanMembrane ProteinsIsoenzymesHeme oxygenaseDisease Models Animal030104 developmental biologyEndocrinologychemistryCyclooxygenase 2Prostaglandin-Endoperoxide Synthases030220 oncology & carcinogenesisHeme Oxygenase (Decyclizing)ImmunologyMacrophages Peritonealbiology.proteinHeminFemaleCyclooxygenaseNitric Oxide Synthasemedicine.symptomHeme Oxygenase-1medicine.drugHeminExperimental Biology and Medicine
researchProduct

Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis.

2017

Major reactive oxygen species (ROS)–producing systems in vascular wall include NADPH (reduced form of nicotinamide adenine dinucleotide phosphate) oxidase, xanthine oxidase, the mitochondrial electron transport chain, and uncoupled endothelial nitric oxide (NO) synthase. ROS at moderate concentrations have important signaling roles under physiological conditions. Excessive or sustained ROS production, however, when exceeding the available antioxidant defense systems, leads to oxidative stress. Animal studies have provided compelling evidence demonstrating the roles of vascular oxidative stress and NO in atherosclerosis. All established cardiovascular risk factors such as hypercholesterolemi…

0301 basic medicinemedicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyOxidative phosphorylationBiologymedicine.disease_causeNitric OxideNitric oxide03 medical and health scienceschemistry.chemical_compoundSpecies SpecificityInternal medicinemedicineAnimalsHumansXanthine oxidasechemistry.chemical_classificationReactive oxygen speciesNitric Oxide Synthase Type IIIAtherosclerosisEndothelial stem cellOxidative Stress030104 developmental biologyEndocrinologychemistryEndothelium VascularCardiology and Cardiovascular MedicineReactive Oxygen SpeciesOxidative stressNicotinamide adenine dinucleotide phosphateCirculation research
researchProduct

Type IV Laryngotracheoesophageal Cleft Associated with Type III Esophageal Atresia in 1p36 Deletions Containing the RERE Gene: Is There a Causal Role…

2018

The causes of embryological developmental anomalies leading to laryngotracheoesophageal clefts (LTECs) are not known, but are proposed to be multifactorial, including genetic and environmental factors. Haploinsufficiency of the RERE gene might contribute to different phenotypes seen in individuals with 1p36 deletions. We describe a neonate of an obese mother, diagnosed with type IV LTEC and type III esophageal atresia (EA), in which a 1p36 deletion including the RERE gene was detected. On the second day of life, a right thoracotomy and extrapleural esophagus atresia repair were attempted. One week later, a right cervical approach was performed to separate the cervical esophagus from the tra…

0301 basic medicinemedicine.medical_specialtyType IV Laryngotracheoesophageal Cleft Type III Esophageal Atresia 1p36 Deletions RERE Genemedicine.medical_treatmentAnastomosisGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineMedicineThoracotomyEsophagus030223 otorhinolaryngologyEpigenomicsbusiness.industrylcsh:RJ1-570lcsh:PediatricsGeneral Medicinemedicine.diseasePhenotype030104 developmental biologymedicine.anatomical_structureAtresiaFailure to thrivemedicine.symptombusinessHaploinsufficiencyCase Reports in Pediatrics
researchProduct

Risk tables for discrimination tests

1993

Abstract Duo-trio and triangle test are often used in the food industry for the purpose of declaring two products non-distinguishable. In that situation, it is much more important to control the power of the test rather than the type 1 error risk. This paper makes available by e-mail a SAS ® macro, called BINRISKS, for computing type 1 and type 2 risks for any one-tailed binomial test and for any level of the percentage above chance to be detected. Using this macro, two sets of tables have been compiled. The first table includes for any total number of responses below 50, for any number of correct responses and for three levels of the percentage above chance to be detected, the correspondin…

0303 health sciencesNutrition and Dietetics030309 nutrition & dieteticsBinomial test04 agricultural and veterinary sciences[SDV.IDA] Life Sciences [q-bio]/Food engineering040401 food scienceDiscrimination testingTest (assessment)03 medical and health sciences0404 agricultural biotechnology[SDV.IDA]Life Sciences [q-bio]/Food engineeringStatisticsEconometricsTable (database)MacroComputingMilieux_MISCELLANEOUSFood ScienceTriangle testMathematicsType I and type II errorsFood Quality and Preference
researchProduct

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19

2021

2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)LipoproteinsEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Familial hypercholesterolemia030204 cardiovascular system & hematologyHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicinePandemicInternal MedicinemedicineHumansHyperlipoproteinemia Type IILife StylePandemicsLetter to the Editor030304 developmental biology0303 health sciencesNutrition and DieteticsSARS-CoV-2Life stylebusiness.industryHomozygoteCOVID-19medicine.diseaseImmunologyBlood Component RemovalCardiology and Cardiovascular MedicinebusinessLipoprotein apheresisJournal of Clinical Lipidology
researchProduct

Metabolic shift of polyphosphate-accumulating organisms with different levels of polyphosphate storage

2012

Previous studies have shown that polyphosphate-accumulating organisms (PAOs) are able to behave as glycogen-accumulating organisms (GAOs) under different conditions. In this study we investigated the behavior of a culture enriched with Accumulibacter at different levels of polyphosphate (poly-P) storage. The results of stoichiometric ratios Gly degraded/HAc uptake, PHB synthesized/HAc uptake, PHV synthesized/HAc uptake and P release/HAc uptake confirmed a metabolic shift from PAO metabolism to GAO metabolism: PAOs with high poly-P content used the poly-P to obtain adenosine tri-phosphate (ATP), and glycogen (Gly) to obtain nicotinamide adenine dinucleotide (NADH) and some ATP. In a test whe…

Accumulibacter Type IIWaste component removalUnclassified drugPhysiologyChemical compositionMicrobial metabolismStorageWastewaterNicotinamide adenine dinucleotidePolyhydroxyalkanoic acidchemistry.chemical_compoundBacteriumBioreactorsPolyphosphatesGlycolysisAnaerobiosisBiomassPolyphosphate-accumulating organismsWaste Management and DisposalAccumulibacter Type IGlycogen accumulating organismPriority journalWater Science and TechnologyFluorescence microscopyPolyhydroxyvalerateSewageGlycogenHydrolysisFluorescence in situ hybridizationEcological ModelingPhosphorusHydrogen-Ion ConcentrationBioaccumulationPollutionStoichiometryWaste treatmentPolyphosphate-accumulating organismsBiodegradation EnvironmentalEnhanced biological phosphorus removalBiochemistryGlycogen-accumulating metabolism (GAM)Nicotinamide adenine dinucleotideAccumulibacter type 1Accumulibacter type 2GlycolysisGlycogenMetabolic Networks and PathwaysAccumulibacterAdenosine triphosphateEnvironmental EngineeringBiologyAcetic acidArticleAssociative storagePolyphosphate-accumulating metabolism (PAM)PolyphosphateGlycogen-accumulating organismsGlycogen-accumulating metabolismsTECNOLOGIA DEL MEDIO AMBIENTEPolyphosphate accumulating organismCivil and Structural EngineeringPolyphosphate-accumulating organisms (PAO)BacteriaPolyphosphateMetabolismIn situ measurementGlycogen-accumulating organisms (GAO)Polyphosphate-accumulating metabolismsNonhumanAmidesCarbonMetabolismchemistryPolyphosphate (poly-P)Bacterial metabolismCell cultureVolatilizationWater Research
researchProduct

Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease

2011

The aim of this paper is to review the latest data on the pharmacological modulation of asymmetric dimethylarginine in human disease. When the terminal nitrogens of the guanidine portion of an arginine become methylated through the action of N-methyl transferases, two chemically close, but physiologically different amino acids are synthesized: symmetric and asymmetric dimethylarginine. The vascular origin of asymmetric dimethylarginine and its inhibitory activity on endothelial nitric oxide synthase give it an important role in certain diseases in which microcirculation is compromised: hypertension, atherosclerosis, inflammatory bowel disease, and diabetes. This review discusses the role th…

Adrenergic Antagonistsmedicine.medical_specialtyAngiotensinsNitric Oxide Synthase Type IIIArginineHypercholesterolemiaPeroxisome Proliferator-Activated ReceptorsHyperhomocysteinemiaReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorPharmacologyArginineBiochemistryNitric oxideDiabetes Complicationschemistry.chemical_compoundInternal medicineDrug DiscoveryAdrenergic antagonistmedicineHumansVascular DiseasesPharmacologychemistry.chemical_classificationVascular diseaseMicrocirculationOrganic Chemistrymedicine.diseaseAngiotensin IIEndocrinologychemistryHypertensionMolecular MedicineKidney DiseasesFarnesoid X receptorHydroxymethylglutaryl-CoA Reductase InhibitorsAsymmetric dimethylarginineCurrent Medicinal Chemistry
researchProduct